Familial adenomatous polyposis and Lynch syndrome are distinct inherited colorectal cancer syndromes: FAP is an adenomatous polyposis condition driven by germline APC mutations that produces hundreds to thousands of colon polyps, while Lynch syndrome is a DNA mismatch repair defect that typically produces few or no polyps but sharply raises colorectal and endometrial cancer risk. The two differ in causative genes, polyp burden, surveillance timing, and the role of surgery.
Both conditions are autosomal dominant, meaning a parent with the mutation has a 50 percent chance of passing it to each child. Both cause early-onset colorectal cancer when unmanaged. Beyond those shared features, they diverge at nearly every level that matters for screening, surgery, and family testing.
Two different failure modes in the colon lining
FAP begins with a broken gatekeeper. The APC gene encodes a protein that tags a growth-promoting protein called beta-catenin for destruction. When APC is mutated, beta-catenin accumulates, and cells in the colon lining keep receiving growth signals they should not. The result is a field of hundreds to thousands of adenomatous polyps, which usually appear in the teens or early twenties. Cancer emerges when additional mutations accumulate in that polyp field, so the risk is a function of polyp number and time.
Lynch syndrome begins with broken proofreading. Mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) normally fix errors made when DNA is copied. When repair fails, errors pile up in short repetitive DNA sequences called microsatellites. This creates microsatellite instability, a mutational signature that drives cancer through rapid accumulation of errors rather than through a polyp field. Polyps may be few or absent, and cancers can arise from flat mucosa that never passed through a visible polyp stage.
That mechanistic difference explains the clinical split. In FAP, the colon visibly declares its risk through polyps, so surveillance is about counting and removing them. In Lynch syndrome, the colon often looks normal, so surveillance is about timing colonoscopy to catch lesions early and about tracking cancers outside the colon, especially endometrial cancer in women.
Quantified context: polyp burden, lifetime risk, and timing
The numbers separate the syndromes clearly. Classic FAP, defined as more than 100 adenomas, carries a near-100 percent lifetime colorectal cancer risk if the colon is left in place. Attenuated FAP, with roughly 10 to 99 adenomas, carries a lower but still substantially elevated risk and presents later. Lynch syndrome carries a lifetime colorectal cancer risk that varies by gene, generally in the range of about 20 to 50 percent depending on which mismatch repair gene is affected, with MLH1 and MSH2 carriers at the higher end.
Extracolonic risk also differs. FAP brings duodenal adenomas and duodenal cancer risk, desmoid tumors, osteomas, dental abnormalities, and congenital hypertrophy of the retinal pigment epithelium. Lynch syndrome brings endometrial cancer risk that can rival or exceed colorectal risk in women, plus ovarian, gastric, small bowel, urinary tract, and other cancers depending on the gene.
Age of onset differs as well. FAP polyps typically appear in adolescence, and cancer can occur in the twenties or thirties without intervention. Lynch syndrome colorectal cancers cluster in the forties and fifties, earlier than sporadic cancer but later than classic FAP. These are population patterns, not individual predictions.
Edge cases that complicate the picture
Attenuated FAP is the most common trap. A patient with 20 adenomas does not meet the classic polyp count but may still carry an APC mutation. Biallelic mismatch repair deficiency, a rare recessive condition, causes a completely different and far more aggressive childhood cancer syndrome than Lynch syndrome, and it is not managed like Lynch syndrome. Some families carry variants of uncertain significance, which are not the same as pathogenic mutations and should not trigger surgery decisions on their own.
A counterintuitive detail: in Lynch syndrome, a normal colonoscopy does not mean the colon is safe. Cancers can develop rapidly between exams, which is why surveillance intervals are shortened and why some guidelines discuss aspirin chemoprevention in selected carriers. In FAP, by contrast, the polyp burden itself is the actionable signal, and the decision is when to remove the colon, not whether polyps are present.
Another professional caveat: serrated polyposis syndrome can resemble attenuated FAP in polyp count but has a different genetic basis and different surveillance logic. Misclassifying it changes management.
Misconceptions worth correcting
The most common misconception is that FAP and Lynch syndrome are interchangeable "hereditary colon cancer" labels. They are not. FAP is a polyposis syndrome; Lynch syndrome is a mismatch repair deficiency syndrome. Confusing them leads to the wrong surveillance schedule, the wrong surgical conversation, and the wrong extracolonic screening.
A second misconception is that a negative family history rules out either condition. De novo mutations occur in both, and incomplete penetrance or early deaths in prior generations can mask a family pattern. A third is that polyp count alone diagnoses FAP; genetic testing confirms it. A fourth is that Lynch syndrome always shows abnormal immunohistochemistry; staining can be normal in some MSH6 and PMS2 cases, so gene sequencing matters.
Practical actions and thresholds
Red flag: more than 10 adenomas at any age, or any adenomas before age 40, warrants genetic evaluation for polyposis syndromes. Red flag: colorectal cancer before age 50, or endometrial cancer at any age, warrants mismatch repair testing and Lynch syndrome evaluation. Red flag: a family history of multiple Lynch-associated cancers across generations should prompt cascade genetic testing. Confirm the diagnosis with germline genetic testing, not polyp counts or family history alone. For FAP, begin colonoscopy in the early teens and discuss colectomy when polyp burden becomes unmanageable, typically in the late teens to twenties. For Lynch syndrome, begin colonoscopy at age 20 to 25, or 2 to 5 years before the earliest family cancer, and repeat every 1 to 2 years. Refer women with Lynch syndrome to gynecologic care for endometrial cancer risk discussion, including risk-reducing surgery options after childbearing.
The thresholds above reconcile because they measure different things. Polyp count is a FAP trigger; age at cancer and tumor type are Lynch triggers. A patient can meet one and not the other.
Timeline comparison
| Feature | Familial adenomatous polyposis | Lynch syndrome |
|---|---|---|
| Typical polyp appearance | Teens to early twenties | Often none or few, any age |
| Polyp count | Hundreds to thousands (classic); 10 to 99 (attenuated) | Usually fewer than 10 |
| Colorectal cancer risk if unmanaged | Near 100 percent (classic FAP) | Roughly 20 to 50 percent, gene-dependent |
| Typical cancer age without surveillance | Twenties to thirties | Forties to fifties |
| First surveillance colonoscopy | Early teens | Age 20 to 25, or 2 to 5 years before earliest family case |
| Surveillance interval | Every 1 to 2 years until colectomy | Every 1 to 2 years |
| Signature extracolonic concern | Duodenal adenomas, desmoids | Endometrial, ovarian, gastric, urinary tract cancers |
| Preventive surgery role | Colectomy is standard when burden is high | Risk-reducing gynecologic surgery is an option; colectomy is not routine |
Limitations of what the evidence can say
Genetic risk estimates are population averages derived from family studies, and they shift as testing expands and variants are reclassified. A pathogenic variant in one family may behave differently from the same variant in another because modifier genes and environment matter. Penetrance is incomplete in Lynch syndrome, so some carriers never develop cancer, and predicting which carriers will is not currently possible.
Screening intervals are guideline recommendations, not guarantees. Colonoscopy misses lesions, particularly flat ones in Lynch syndrome, and adherence matters as much as schedule. Chemoprevention evidence, including aspirin, is evolving and does not replace surveillance.
Nothing here constitutes a diagnosis or treatment plan. Anyone with a red-flag personal or family history should see a genetics professional, because the management difference between these two syndromes is large and the testing pathway is well established.